XLO

Xilio Therapeutics, Inc.

A biotechnology company in Waltham, Massachusetts, that designs cancer treatments meant to switch on only inside a tumor, so the body's own immune system attacks the cancer while healthy tissue is left alone. Its pipeline includes tumor-activated proteins like an IL-12 therapy, built on a masking platform the company calls GPS. Founded in 2016 as Akrevia Therapeutics and renamed Xilio in 2020, the name comes from the Latin phrase "ex nihilo," meaning "out of nothing," nodding to the idea of creating a new kind of cancer medicine.